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BRIEF COMMUNICATION
ASEPTIC MENINGITIS IN A LARGE MMR VACCINE CAMPAIGN (590,609 PEOPLE) IN CURITIBA,
PARANÁ, BRAZIL, 1998
Walter Oleschko ARRUDA(1) & Charles KONDAGESKI(2)
SUMMARY
The aseptic meningitis after Measles-Mumps-Rubella vaccine (MMR) is a well recognized complication, and different incidences
have been observed in several studies. We retrospectively analyzed forty cases of aseptic meningitis, during a large public immunization
campaign (1998) in Curitiba, Southern Brazil (590,609 people), admitted in our Service. The vaccine utilized was Leningrad-3-
Zagreb mumps strain, Edmonston-Zagreb measles strain, and RA 27#3 rubella strain. In all county, a total number of 87 cases were
reported, resulting in a incidence of 1.7 cases per 10,000 given doses . The mean age was 23.7 ± 12.8 years. The female:male ratio was
1.35:1. Severe headache with meningismus (92.5%), fever (87.5%), nausea/vomiting (82.5%) were the most common clinical findings.
Three cases (7.5%) developed mild mumps. All patients underwent cerebrospinal fluid (CSF) tap with the following findings:
mononuclear pleocytosis from 100 to 500 cells/mm3 in 17 cases (42.5%; 257.5 ± 260.6 cells/mm3); increased protein 28 cases
(67.5%; 92.1 ± 76.9 mg/dL); glucose was normal in all cases (56.8 ± 11.2 mg/dL) except in 4 (10%) cases, which presented less than
44 mg/dL. All serological tests (latex to bacterial meningitis, Cryptococcus, cysticercosis, VDRL) and bacteriological cultures were
negative. Virus identification were also negative in 8 samples. None of the patients had neurological deficits or related symptoms after
one year of onset. We believe the benefit of vaccination clearly outweights the incidence of benign vaccine-associated meningitis.
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Aseptic meningitis (AM) is a well-recognized complication of
mumps vaccine typically occurring 2-4 weeks after immunization and
resolving without sequelae. North American studies have shown a risk
of post-vaccinal meningitis between 0.4 and 10 per million doses with
the use of Jeryl Lynn strain1. In Japan, a higher rate of AM with Urabe
Am9 strain was reported2,3.
We report the findings of aseptic meningitis during a large vaccination
campaign (MMR) in Curitiba, Southern Brazil, in 1998.
METHODS
From October 24, 1998 to November 30, 1998, 590,609 people with
ages from 1 to 39 years-old and living in Curitiba, Southern Brazil
(25°25’40”S; 49°16’23”W-GR), were vaccinated with Leningrad-3-
Zagreb mumps strain, Edmonston-Zagreb measles strain, and RA 27#3
rubella strain (Measles, Mumps and Rubella Vaccine Live, Attenuated
(Freeze-Dried – Serum Institute of India Ltd, India). The reason for this
campaign was an alarming increase of measles cases during 1998.
The estimated 1998 Curitiba population in this age interval was
1,102,578 people. Notification of all cases of aseptic meningitis to the
County Health Secretary is obligatory by law.
A total number of 87 cases was reported, giving an incidence of
vaccine-associated meningitis in our study of 1.7 per 10,000 doses. Forty
patients out of the 87 cases of post-vaccination AM were admitted to
our Service, giving an annual prevalence rate of 29/1,000 cases, in
comparison with an average annual rate of 5/1,000 rate in other years
(from 1994 to 1997).
The mean age of our patients was 23.7 ± 12.8 years. The female:male
ratio was 1.35:1. Signs/symptoms of meningitis occurred between 11
and 20 days after vaccination in most cases (60%) (mean 21 ± 8.7 days).
Severe headache with meningismus (92.5%), fever (87.5%), nausea/
vomiting (82.5%) were the most common clinical findings. Three cases
(7.5%) developed mild mumps. All patients underwent cerebrospinal
fluid (CSF) tap within 48 hours of onset, with the following findings:
mononuclear pleocytosis from 100 to 500 cells/mL in 17 cases (42.5%;
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257.5 ± 260.6 cells); increased protein 28 cases (67.5%; 92.1 ± 76.9
mg/dL); glucose was normal in all cases (56.8 ± 11.2 mg/dL) except in
4 (10%) cases, which presented less than 44 mg/dL. All serological tests:
latex to bacterial meningitis (latex detection of soluble antigens: N.
meningitidis A., C., Y/W135., B.; E. coli K1, H. influenza, S. pneumoniae,
Streptoccocus B. – PASTOREX MENINGITIS, Bio Rad, France),
Cryptococcus (Cryptococcal Antigen Latex Agglutination – Meridian
Diagnostics, Inc. USA), cysticercosis (immunoenzymatic test for
neurocysticercosis in cerebrospinal fluid – Biolab-Mérieux S.A., Brazil)
and VDRL (Syphilis serological antigen screening – Laborclin, Brazil)
and bacteriological cultures were negative. Eight samples were sent for
detection of mumps virus and were negative (Adolfo Lutz Institute, São
Paulo). Symptomatic treatment with parental hydration, anti-emetics,
analgesics, and bed rest was effective in all cases.
Most patients (38) were completely asymptomatic after 30 days.
After one year, all forty patients were reviewed and were in good health
without noticeable sequelae.
There was a marked drop of cases of measles during the following
two years after this campaign.
COMMENTS
There was a relatively high incidence of post-vaccination AM with
the use of Leningrad-3-Zagreb strain (1.7 per 10,000 doses), but lower
to other reported series (9-10 per 10,000 doses)4,5. The Urabe strain was
also associated with a higher risk of AM when compared to the Jeryl-
Lynn strain in UK6, and gave numbers very close to ours (risk estimate
of 1 per 11,000 doses). Comparative data of these 3 mumps strains on
long-term antibody persistence and protective efficacy are still lacking.
We believe the benefit of vaccination clearly outweighs the incidence of
benign vaccine-associated meningitis.
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RESUMO
Meningite asséptica na campanha de vacinação pública tríplice
viral (590.609 indivíduos) em Curitiba, Paraná, Brasil, 1998
A incidência de meningite asséptica após vacina tríplice viral (MMR)
é diferente em diversos estudos. Analisamos retrospectivamente quarenta
casos de meningite asséptica, relacionados a uma campanha de vacinação
pública para cobertura tríplice viral em Curitiba, PR, Brasil, ano de 1998.
A vacina utilizada foi a Leningrado-3-Zagreb para caxumba, Edmonston-
Zagreb para sarampo e RA27#3 para rubéola. Um total de 87 casos
foram relatados, resultando em uma incidência de 1,7 casos por 10.000
doses. A idade média dos pacientes foi 23,7 ± 12,8 anos. A relação
feminino/masculino foi 1,35:1. Cefaléia intensa com sinais
meningorradiculares (92,5%), febre (87,5%), náuseas e vômitos (82,5%)
foram os achados clínicos mais comuns. Três casos (7,5%) desenvolveram
caxumba branda. Todos os pacientes foram submetidos a punção lombar
para obtenção de líquor, com os seguintes achados: pleocitose
mononuclear de 100 a 500 células em 17 casos (42,4%; 257 ± 260,6
células/mm3); proteínas aumentadas em 28 casos (67,5%; 92,1 ± 76,9
mg/dL) e glicose (56,8 ± 11,2 mg/dL). Os testes sorológicos (látex para
meningites, Cryptococcus, cisticercose, sífilis) e culturas bacteriológicas
foram negativas. Identificação viral também foi negativa em 8 casos.
Nenhum dos pacientes desenvolveu déficits neurológicos ou sintomas
relacionados após um ano do início do quadro. Acreditamos que o
benefício da vacinação claramente supera os eventuais efeitos da
meningite asséptica após vacinação MMR devido ao seu caráter e
evolução benignos.
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